EGFR and neoplasm: Similarly, TAM receptor and ligand expression were assessed in 3 paired pre- and posttreatment tumor biopsies from patients with EGFRMT NSCLC that progressed during treatment with OSI, including one tumor that acquired an EGFR-C797S mutation (Supplemental Table 5).